Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K L Hyrich

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Pharmacogenomics Journal|July 17, 2013
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortJ Bluett, I Ibrahim, D Plant, et al.
Annals of the Rheumatic Diseases|April 4, 2008
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterM J Harrison, W G Dixon, K D Watson, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics RegisterJ B Galloway, K L Hyrich, L K Mercer, et al.
Scandinavian Journal of Rheumatology|May 21, 2025
Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritisS F Ling, P Ho, M Bukhari, et al.
Annals of the Rheumatic Diseases|April 1, 2008
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisC Potter, K L Hyrich, A Tracey, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Pharmacogenomics Journal|July 17, 2013
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortJ Bluett, I Ibrahim, D Plant, et al.
Annals of the Rheumatic Diseases|April 4, 2008
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterM J Harrison, W G Dixon, K D Watson, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics RegisterJ B Galloway, K L Hyrich, L K Mercer, et al.
Scandinavian Journal of Rheumatology|May 21, 2025
Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritisS F Ling, P Ho, M Bukhari, et al.
Annals of the Rheumatic Diseases|April 1, 2008
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisC Potter, K L Hyrich, A Tracey, et al.
Pageof 2